A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/44 (2006.01) A61K 31/4439 (2006.01) A61P 1/04 (2006.01)
Patent
CA 2489730
The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspects of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro, esophageal reflux disease, as well as for the treatment of regurgitation and asthma.
la présente invention concerne l'utilisation d'antagonistes du récepteur du glutamate métabotropique de type 5 dans l'inhibition du relâchement passager du sphincter oesophagien inférieur. Un autre aspect de l'invention porte sur l'utilisation d'antagonistes du récepteur du glutamate métabotropique de type 5 pour le traitement du reflux gastro-oesophagien, ainsi que pour le traitement de la régurgitation et de l'asthme.
Lehmann Anders
Mattsson Jan
Stormann Thomas M.
Astrazeneca Ab
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Nps Pharmaceuticals Inc.
LandOfFree
Use of mglur5 antagonists for the treatment of gerd does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of mglur5 antagonists for the treatment of gerd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of mglur5 antagonists for the treatment of gerd will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1676528